Article Name Invitro & Invivo Diagnostic
The NMPA acceptance of Chance Pharma’s first new drug application advances CXG87, an improved budesonide/formoterol dry powder inhalation therapy, toward potential commercialisation in China.
08th May, 2026
Jointly developed by SGH, SingHealth and MOHT, LEA-Net uses patient data to identify individuals at higher risk of lower extremity amputation three to five years before foot ulcers and infections develop.
08th May, 2026
Expansion of Vanquish procedures highlights growing adoption of minimally invasive water vapour ablation technology for prostate disease
07th May, 2026
Together, these announcements represent a step forward in increasing accessibility to complex DNA
06th May, 2026
Funding to accelerate development of real-time imaging solutions aimed at improving surgical precision and patient outcomes
30th April, 2026
Calidar completes enrollment in a first-in-human study of its 4D Mammography system, advancing a next-generation imaging platform designed to enhance breast cancer detection through molecular-level diagnostics.
29th April, 2026
Deployment of compact point-of-care brain PET scanners reflects growing demand for earlier, accessible neurodiagnostics in community settings
24th April, 2026
The respiratory system has evolved efficient mechanisms to clear inhaled particles
23rd April, 2026
The company is seeking to overcome long-standing limitations of conventional HIFU systems and expand the role of non-invasive therapies in clinical practice
22nd April, 2026
Regulatory milestone expands potential use of anti-CD20 therapy in lupus, building on prior success in lupus nephritis
21st April, 2026
Gadopiclenol-based contrast agent enables high-quality imaging at reduced gadolinium exposure, supporting safer diagnostic workflows
20th April, 2026
CStone presents preclinical data on three differentiated antibody-drug conjugates, including a dual-target EGFR/HER3 candidate
20th April, 2026
α-Sight™ integrates advanced SPECT imaging, radiochemistry, and quantitative analysis to enable precise tracking of alpha-emitting therapies
16th April, 2026
AI will soon enable clinicians to predict ovulation and optimize IVF cycle timing, improving outcomes and operational efficiency.
16th April, 2026
Phase two collaboration aims to expand access to streamlined genomic workflows for infectious disease research
15th April, 2026
Integrated automated platform unifies multi step sample preparation to improve consistency, reduce operational complexity, and enable high precision workflows across MRD testing and advanced molecular diagnostics
15th April, 2026
These strengths enhance our platform and position us to meet the growing demand for high-quality teleradiology services in outpatient imaging
02nd April, 2026
QuidelOrtho is strengthening its global immunoassay offering through a new partnership aimed at expanding assay availability beyond its existing VITROS diagnostic system portfolio
12th March, 2026
© 2023 MM Activ Sci-Tech Communications. All rights reserved | Disclaimer